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A ­ Introduction 
A.1 – L. monocytogenes and Listeriosis 
Listeria monocytogenes is a food-borne Gram-positive pathogen that is the causative 
agent of listeriosis (2). Listeriosis is a life-threatening illness, which is primarily a threat to 
immunocompromised individuals and pregnant women.  L. monocytogenes causes various 
symptoms ranging from a mild chill and gastroenteritis to more severe illnesses and diseases 
such as premature birth or miscarriage, and meningitis in newborns.  In immunocompromised 
adults, the bacteria can cause septicemia or meningitis (4).   
A.2 – Listeriolysin O (LLO) as the major virulence factor 
The major virulence factor of L. monocytogenes is listeriolysin O (LLO).  L. 
monocytogenes is a facultatitve, intracellular pathogen (7) that can invade phagocytic and non-
phagocytic cells (1).  In non-phagocytic cells, L. monocytogenes actively invades the non-
phagocytic cell via interactions between the internalin surface proteins (Internalin A and 
Internalin B) and the host membrane receptors E-cadherin and HGF factor (5).  LLO has been 
shown to play crucial roles in bacterial intracellular survival by mediating the disruption of the 
host vacuolar membranes after uptake of the bacteria, hence releasing the bacteria into the 
cytosol (2).  
A.3 – LLO and the CDC family of Toxins 
 LLO is a member of the Cholesterol-Dependent Cytolysin (CDC) family of pore-
forming toxins (2).  The CDC proteins share 40-70 % amino acid sequence similarity, which 
allows for the assumption that they share similar three-dimensional structures and mechanisms of 
action (6).  The crystal structures of the CDC proteins Perfringolysin O (PFO) and 
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Intermedilysin (ILY) have been determined (7).  These two proteins consist of four domains 
similar in structure, which are most likely representative of all of the family members.  PFO and 
LLO present 42 % amino acid sequence similarity and 68 % similarity in Domain 4 (7).  
Therefore, PFO is used to model the structure of LLO (Figure 1).   
A.4 – Pore Formation 
The exact mechanism for CDC binding and pore-formation is not completely understood; 
however, it is thought that CDCs bind to the cell membrane via domain 4 at the tryptophan rich 
undecapeptide sequence and loops L1 to L3.  The protein then oligomerizes in a ring structure 
called a pre-pore complex before penetrating the membrane to form a pore.  The mechanism of 
membrane perforation has been extensively studied and it is thought that large scale 
conformational remodeling in domain 3 unfolds the α-helices to span the membrane and create a 
pore.  The pore is composed of 35 to 50 monomeric proteins and has a diameter of about 300 
Angstroms (2). 
A.5 – Project Objective 
The goal of my project was to obtain recombinant LLO proteins which, when 
fluorescently labeled, can be used to determine the spatiotemporal dynamics of LLO with the 
host cells. Through the experimental approaches of my project, we will generate a recombinant 
toxin which can be fluorescently labeled so that the mechanism of action of the domains of LLO 
can be studied.  In order to achieve this goal, two major steps had to be taken:  
1) Construct, purify, and fluorescently label recombinant toxin.  
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2) Analyze, by hemolytic assay, the activity of the fluorescently labeled recombinant 
toxin and determine if the labeled toxin binds to host membranes by fluorescence 
microscopy 
This project is important because it will lay the groundwork for understanding the 
interactions between CDCs and the host cell, by using LLO as a model CDC.  The results will 
lead to a better understanding of diseases generated by Gram-positive bacteria.  Also our results 
will allow us to refine the design of antitoxins to fight infectious diseases. 
 
Figure 1.  Determined crystal structure of PFO is shown on the left and the modeled structure of LLO is 
shown on the right.  The four domains are distinguished by different colors and have been properly labeled.  
The undecapeptide sequence in domain 4 has been shown in black and the pore forming helices have been 
labeled in the PFO structure. 
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B ­ Materials and Methods 
B.1 ­ Site­Directed Mutagenesis 
Construction of the cysteine-free LLOC484A–6xHis 
 Mutation of the Cys to an Ala in D4 
The first step in creating protein mutants began through manipulation of plasmid pet29b 
with an encoding region for LLO and resistance to the antibiotic kanamycin.  This plasmid 
contained a C-terminal 6xHis tag in the LLO gene, which was later used for protein purification.  
Initially, the plasmid was purified using a DNA miniprep kit (Qiagen).   
Mutagenesis 
The initial step was to replace the only cysteine codon at amino acid 484 within the LLO 
sequence with an alanine codon.  This was attained through performing a site-directed 
mutagenesis with Stratagene’s Quikchange site-directed mutagenesis kit.  To obtain the desired 
mutation, two complementary oligonucleotides were designed and ordered (Integrated DNA 
Technologies, Inc.) that contained the desired base pair mutation flanked by unmodified 
nucleotide sequence (Table 1).  Primers were designed so that the mutation was in the middle of 
the primer sequence.  Primers needed at least one G or C at each end, and a total of 25-45 bp to 
obtain a melting temperature (Tm) of 78°C or higher.  The primers needed a Tm of 78°C so they 
could bind to DNA during the annealing and elongation phases of the Polymerase Chain 
Reaction (PCR).  The primers were reconstituted in water to give final concentrations of 125 
ng/μl.  This was to facilitate adding primers to the PCR reaction mixture.  
AA mutation 
(original-
>mutant) 
Original LLO plasmid DNA 
sequence (Top Strand) 
Forward Primer (Tm) Reverse Primer (Tm) 
AA #484 
(Cys->Ala) 
5’-ATTAATGTTTACGCTAAAG 
AATGCACTGGTTTAGCTTGGGAAT
GG–3’ 
5’-ATTAATGTTTACGCTAAAG 
AAGCGACTGGTTTAGCTTGGGA
ATGG–3’ (Tm = 78.5°C) 
5’-CCATTCCCAAGCTAAACCA 
GTCGCTTCTTTAGCGTAAACAT
TAAT–3’ (Tm = 78.5°C) 
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AA #27 
(Ala->Cys) 
5’-GAAGGAGATATACATATGA 
AGGATGCATCTGCATTCAATAA 
AGAAAATTCAATTTCATCC-3’ 
5’-GAAGGAGATATACATATGA 
AGGATTGCTCTGCATTCAATAA 
AGAAAATTCAATTTCATCC-3’
(Tm = 78.2°C) 
5’-GGATGAAATTGAATTTTCT 
TTATTGAATGCAGAGCAATCC 
TTCATATGTATATCTCCTTC-
3’ (Tm = 78.2°C) 
AA #69 
(Asp->Cys) 
5’-GAAATCGATAAGTATATAC 
AAGGATTGGATTACAATAAAAA 
CAATGTATTAGTATACCACG-3’ 
5’-GAAATCGATAAGTATATAC 
AAGGATTGTGTTACAATAAAAA 
CAATGTATTAGTATACCACG-
3’ (Tm = 78.6°C) 
5’-
CGTGGTATACTAATACATTG 
TTTTTATTGTAACACAATCCTT
G TATATACTTATCGATTTC-
3’ (Tm = 78.6°C) 
AA #274 
(Val->Cys) 
5’-CCAGATTTTTCGGCAAAGC 
TGTTAAAGAGCAGTTGCAA GCG–
3’ 
5’-CCAGATTTTTCGGCAAAGC 
TTGCAAAGAGCAGTTGCAA 
GCG–3’ (Tm = 79°C) 
5’-CGCTTGCAACTGCTCTTT 
AGTGCAAGCTTTGCCGAAAAAT 
CTGG-3’ (Tm = 79°C) 
AA #275 
(Thr->Cys) 
5’-CCAGATTTTTCGGCAAAGC 
TGTTACTAAAGAGCAGTTGCAA 
GCGC–3’ 
5’-CCAGATTTTTCGGCAAAGC 
TGTTTGTAAAGAGCAGTTGCAA 
GCGC–3’ (Tm = 81.4°C) 
5’-CGCTTGCAACTGCTCTTT 
ACAAACAGCTTTGCCGAAAAAT 
CTGG-3’ (Tm = 81.4°C) 
TABLE 1. Primers used to mutate the LLO gene.  The codon highlighted in blue represents the original codon which 
was mutated and the codons highlighted in red represent the mutagenic region of the oligonucleotide primer. 
 
The plasmid was then subjected to PCR using the complementary primers.  The reaction 
mixture contained: 125 ng (1 μl) of each primer, 1 μl of dNTP mix, 1 μl of 10x reaction buffer, 
50 ng of pet29b plasmid and water.  The total amount of water added was dependent on the 
volume needed to add 50 ng of plasmid.  As a positive control, the plasmid DNA and 
oligonucleotides were replaced with the PCR control plasmid pWhitescript and the mutagenic 
primers provided by Stratagene.  1 μl of PfuUltra DNA polymerase (2.5 U/μl) was used in each 
mixture.  Each tube was then subjected to PCR in a thermocycler for 16 cycles which served to 
melt the DNA, anneal the primers, and finally elongate the DNA with the desired mutations 
(Table 2).  After PCR, the reaction mixture was placed on ice for 2 minutes to cool.   
Segment Cycles Temperature Time 
1 (denaturation) 1 95°C 30 sec 
2 (denaturation) 16 (18 - control) 95°C 30 seconds 
(annealing)  55°C 1 min 
(elongation)  68°C 7 minutes (5 min – control) 
3 (holding temp) 1 4°C ∞  
Table 2.  PCR cycling protocol for site directed mutagenesis 
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Digestion and Transformation 
The parental DNA in the PCR mixture was then digested with 1 μl of DpnI (10 U/μl) 
restriction enzyme (New England Biolabs).  DpnI digested the parental DNA which had been 
methylated by the XL1-Blue E. coli.  Sample was incubated for 1 hour at 37°C to allow the DpnI 
enzyme to function efficiently.  The plasmid DNA was then transformed into competent XL1-
Blue E. coli cells by adding 5 μl of DNA to 100 μl of competent XL1-Blue cells.  Transformed 
cells were plated on a LB kan plates to select for the bacteria which had taken up the plasmid 
DNA.  Plates were incubated overnight at 37°C. 
Purification and Sequencing of the Mutated Plasmid 
The following day, five colonies were picked from the LB-kan plate. The colonies were 
each inoculated into 5 ml of LB kan broth and allowed to grow overnight. The following 
morning, the plasmids were purified from the bacterial cultures.  The bacterial pellets formed 
during centrifugation were purified using a plasmid purification kit (Qiagen). 
The optical densities at 260 nm and 280 nm (OD260/ OD280) were then measured to 
determine the concentration and purity of the DNA.  The gene encoding for LLO was then 
sequenced to confirm that the mutagenesis was successful.  This was performed by using T7P 
and T7T oligonucleotide primers which attach to the plasmid before and after the LLO gene.  
The sequencing results were aligned using BioEdit DNA alignment software.  After determining 
that the mutation of a Cysteine to an Alanine was successful, the cysteine-free LLO gene 
(LLOC484A–6xHis) became the template sequence for all future reconstructions of the toxin. 
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Construction of LLOC484A–6xHis 
 Insertion of Cys in D1 
The LLOC484A–6xHis encoding gene was subjected to an additional mutation using the 
same site-directed mutagenesis protocol as described above.  Three mutants corresponding to 
different site of mutation were constructed.    All primers were reconstituted in a volume of water 
which gave a final concentration of 125 ng/μl. The amino acids that were selected were 
determined to likely be of lesser importance in the mechanism of action of LLO based upon their 
location within the 3D structure (Figure 1).  Also amino acids were selected around the edges of 
the protein structure because this would allow for measuring FRET between different monomer 
of toxin.  Four point mutations in domain 1 were attempted in order to increase the odds that at 
least one recombinant would maintain activity after purification and fluorescent labeling. 
Conversions of alanine 27, aspartate 69, valine 274, and threonine 275 to cysteine were 
attempted.  Mutagenic primers were used to introduce these mutations into domain 1 of LLO 
which are presented in Table 1. 
Recombinant toxins  (KDa) Mutations 
LLO C484A-6xHis (57) C484 A (TGC→GCG) 
LLO C484A/A27C-6xHis (57) C484A (TGC→GCG) 
A27C (GCA→TGC) 
LLO C484A/D69C-6xHis (57) C484A (TGC→GCG) 
D69C (GAT→TGT) 
LLO C484A/T275C-6xHis (57) C484A (TGC→GCG) 
T275C (AC→TGC) 
Table 3.  Recombinant toxins created via site-directed  
mutagenesis. 
B.2 ­ Protein Purification 
Protein Synthesis 
In order to produce and purify the LLO recombinant toxins, plasmids encoding for each 
recombinant toxin were transformed into BL21 (DE3) E. coli cells.  50 μl of BL21 (DE3) cells 
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were grown overnight on LB kanamycin plates after transformation with 5 μl of each plasmid.  
The following day, a colony was picked and inoculated into 10 ml LB kanamycin broth 
overnight.  Each overnight culture was then added to 500 ml LB kan.  The culture was incubated 
with shaking at 37°C until it reached an OD600 of 0.6.  This was to ensure that the cells were in 
the exponential growth phase before LLO protein synthesis was induced.  LLO production was 
induced by adding 500 μl (1 μl/ml) of the chemical Isopropyl β-D-1-thiogalactopyranoside 
(IPTG), which binds to the LacI product which represses the lac operator that is the promoter for 
the LLO gene.  After 5 hours at 25°C, the culture was divided centrifuged at 3,000 rpm for 45 
min at 4°C (Beckman J2-MC, JA14 rotor).  After centrifugation, the bacterial pellet was frozen 
at -80°C.   
The following day, the bacterial cultures were resuspended in 1.5 ml of 50 mM phosphate 
buffer at pH 8 (1 M NaCl, 5 mM β-Mercaptoethanol, 0.75 mg/ml DNAse I, and 50 μl/(g of E. 
coli) of protease inhibitor).  The E. coli suspension was then lysed in a Mixer Mill 200 (Retsch) 
at -20°C and at a frequency of 30 sec-1 for 9 min.  The lysed cells were centrifuged at 14,000 rpm 
for 30 min at 4°C (Beckman Microfuge 22R). 
Affinity Chromatography 
The clear lysate was then applied to a nickel-nitrilotriacetic acid (Ni-NTA) matrix by 
rotating for two hours at 4°C.  Protease inhibitors were added to the mixture at a concentration of 
50 μl/(g of E. coli) to prevent protein degradation.  The matrix was bound to the LLO protein via 
the 6xHis tag located at the C-terminus of the toxin.  After application to the matrix, the sample 
was thoroughly washed with three different buffers before protein elution.  8 total washes were 
performed with a 50 mM phosphate/acetate buffer at pH 8 (1M NaCl and 5 mM β-
mercaptoethanol).  Six washes were then performed with a 20 mM phosphate/acetate buffer at 
B r u g g e m a n  | 11 
 
pH 6 (1M NaCl, 20mM imidazole, 5 mM β-mercaptoethanol, 0.1 % Tween 20, and 10 % 
glycerol).  After these washes the OD280 of the solution was measured; if the OD280 was less than 
0.01, the final two washes were performed.  These final washes consisted of the previous buffer 
without tween or glycerol.  After each wash, the matrix was centrifuged at 1,500 rpm for 5 
minutes at 4°C in a Beckman Allegra 6R centrifuge to pellet the matrix and aspirate the wash 
buffer.    
Elution 
Once the wash steps were complete, the matrix which contained the protein was 
transferred to a plastic column at 4°C for elution.  This was performed by adding 1.5 ml of 
elution buffer to the column after rinsing the original wash tube with the buffer.  The elution was 
performed with a 50 mM phosphate/ acetate buffer at pH 6 containing 1 M NaCl, 500 mM 
imidazole, and 5 mM β-mercaptoethanol.  An additional 1.5 ml was used to rinse the original 
wash tube a second time, which was immediately applied to the elution column.   The flow 
through was collected in 0.5 ml aliquots. 
The elution profile was analyzed via DC protein assay (Bio-Rad) to determine which 
fraction contained a high concentration of protein.  5 μl of each aliquot was added to a separate 
well in a 96 well plate.  A protein standard was prepared by adding 10 μl of BSA at a 
concentration of 1.75 mg/ml and diluting it in elution buffer via serial dilution.  This protein 
served as a standard for comparison with the protein suspensions from the elution.  25 μl of 
reagent A was added to each well (Bio-Rad). Reagent A is a copper solution that reacts with the 
protein.  After reagent A, 200 μl of reagent B (Bio-Rad) was added to each well.  Reagent B is a 
Folin reagent that is reduced in the presence of the copper-treated protein.  After 15 minutes, the 
absorbance was analyzed at OD750 to determine which fraction contained the elutued protein.   
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Dialysis 
The concentrated toxins were then dialyzed to remove unwanted small molecules.  
Dialysis was performed by injecting the toxin into a Slide-A-Lyzer dialysis cassette (Thermo 
Scientific).  The toxin was dialyzed overnight at 4°C with stirring in a 50 mM phosphate/acetate 
buffer at pH 6 containing 0.5 M NaCl, 1 mM EDTA, and 170 μM TCEP.  The following day the 
cassette was placed in fresh dialysis buffer for an additional 4 hours.  This buffer was similar to 
the first dialysis buffer except it did not contain TCEP.  After dialysis, the OD280 of the protein 
was measured to determine the concentration.  5 μl of the protein was collected and diluted in 95 
μl of elution buffer to test the concentration of the protein without using a significant size of the 
sample.  Dialysis buffer diluted 20x was used as a blank. 
Analysis 
After each major step of the protein purification process, aliquots were collected and 
analyzed in an SDS-PAGE gel.  Also, western blots were performed to ensure that the LLO 
protein was not degraded.  To perform a western blot the LLO protein was run on an SDS-PAGE 
gel and then the protein was transferred to a Polyvinylidene Fluoride (PVDF) membrane.  After 
blotting, non-fat dry milk was applied to the membrane to saturate the PVDF with proteins. A 
rabbit anti-His-tag polyclonal antibody was used as the primary antibody in detection.  The 
secondary antibody was horseradish-peroxidase-linked secondary antibody (anti-rabbit IgG) 
which produces luminescence in proportion to the amount of the primary antibody, and antigen 
product on the membrane. 
B.3 ­­ Fluorescent Coupling 
After the proteins had been purified, they were fluorescently labeled with the molecular 
probe Alexa Fluor 488 (Invitrogen) C5 maleimide.  To optimize labeling, the recombinant 
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proteins were diluted into a labeling buffer to obtain a concentration of 2.8 mg/ml.  The labeling 
buffer used for diluting the proteins was similar to the final dialysis buffer of protein purification 
and consisted of 50 mM phosphate/ acetate, pH 6.8, 0.5 M NaCl, 1 mM EDTA. After dilution, 
the fluorescent probe was added to the protein suspension.  To prepare the dye, 140 μl of 
labeling buffer was added to 1 mg of Alexa Fluor 488.  25 μl (0.2 mg) of dye was then added to 
each mixture.  Each labeling reaction was prepared so that a final volume of 0.5 ml of sample 
was obtained.  The samples were incubated with stirring at 4°C for a total of 5 hours to allow the 
fluorescent probe to couple to the protein at the cysteine residue.  The reaction was protected 
from light by wrapping the tubes with aluminum foil. 
After the 5 hours of incubation, the labeled toxin was separated from the uncoupled dye 
via gel filtration chromatography (Sephadex G25).  The column used was a Sephadex PD-10 
desalting column (GE).  Before application of the sample to the column for filtration, the column 
was prepared by applying 2.5 ml of labeling buffer to equilibrate the column.  The sample was 
then applied to the column.  After the sample had completely entered the column, 2 ml of 
additional labeling buffer was added for a total volume of 2.5 ml.  The flow through was 
collected in aliquots of 1 ml, 1 ml, 0.5 ml, and 0.5 ml for the remaining aliquots.  An additional 
3.5 ml of buffer was added to allow the sample to flow through the column completely.  The 
aliquots that were collected were analyzed by DC protein assay to determine which fractions 
contained the labeled protein.  As a negative control the fluorescent dye was added to the 
LLOC484A toxin. 
After filtration was complete and the proteins had been collected, the OD280 and OD494 
were measured so that the concentration of protein and dye in each sample could be calculated.  
The following equations were used to determine the molar concentration of the protein and the 
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dye to protein ratio. When necessary, the samples were diluted so that the OD280 and OD494 
readings were below 1.0. 
750,75
*)]11.0*494(280[ dilutionAbsAbs −
= [M] concentration of protein.   
][*000,71
*494
Mprotein
dilutionAbs = dye/protein ratio.   
B.4 ­­ Hemolytic Assay 
 After fluorescently labeling the toxins, the hemolytic ability of the proteins was tested.  
First, a suspension of sheep red blood cells 0.2 % (SRBCs) was obtained. 750 μl of stock 10 % 
SRBCs (Lampire) were washed with 30 ml cold Phosphate Buffered Saline at pH 7.4 (PBS) and 
the suspension was centrifuged at 1500 rpm for 15 min at 4°C in a Beckman Coulter Allegra 6R 
centrifuge. The supernatant was aspirated without removing any of the SRBCs.  SRBCs were 
resuspended in 30 ml fresh PBS and the process was repeated for a total of three washes.  After 
the final wash, the SRBCs were resuspended in 30 ml PBS to obtain a SRBC suspension of 0.2 
% in PBS. 
During the preparation of the SRBC solution, a round-bottom 96-well plate was prepared.  
For each protein to be tested, a row was filled with 20 μl PBS (except the first column).  
Additionally, Triton 1 % diluted in PBS and PBS served as positive and negative controls, 
respectively.  20 μl of each LLO protein to be tested was added to column 1 and 2 of each row at 
a concentrations of 0.0026 mg/ml for LLOC484A/T275C-6xHis, 0.0032 mg/ml for LLOC484A/D69C-
6xHis, 0.0044 mg/ml for LLOC484A/A27C-6xHis, 0.45 mg/ml for LLOW492A-6xHis, and 0.01 mg/ml 
for LLO WT-6xHis (Table 4).  A serial dilution of each toxin was performed starting with 20 μl 
from column 2.  This dilution was performed for each row containing an LLO toxin.  200 μl of 
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0.2 % SRBCs in PBS at pH 7.4 was then added to each sample.  All of steps were performed on 
ice to prevent protein degradation.   
Samples were allowed to incubate on ice for 5 min after SRBCs had been added.  Then 
the samples were incubated for 30 minutes at 37°C.  LLOWT was used as a control for the normal 
amount of lysis of SRBCs by LLO.  After incubation and cell lysis, the plate was centrifuged in 
an Allegra 6R centrifuge to pellet the intact red blood cells.  The supernatant containing 
hemoglobin from the lysed red blood cells was then transferred to a flat-bottom 96 well plates so 
that the absorbance of the hemoglobin solution could be measured at 450 nm.  The results were 
analyzed to determine the concentration of each recombinant protein that causes 50 % SRBC 
lysis. 
Toxin Concentration 
LLO WT-6xHis 0.01 mg/ml 
LLO W492A-6xHis 0.45 mg/ml 
LLO C484A/A27C-6xHis 0.0044 mg/ml 
LLO C484A/D69C-6xHis 0.0032 mg/ml 
LLO C484A/T275C-6xHis 0.0026 mg/ml 
Table 4.  Recombinant toxins that were tested in the hemolytic 
assay along with the initial concentration for each serial 
dilution. 
 
B.5 ­­ Fluorescence Microscopy 
Vero Cells Cultured 
After the toxins had been fluorescently labeled and had been determined to maintain their 
pore-forming capabilities, they were tested for their ability to bind to mammalian cell 
membranes.  The cells used were African green monkey kidney epithelial (Vero) cells.  First, 
Vero cells were cultured in a 75 cm2 flask in ATCC complete growth medium.  This was 
Minimal Essential Medium (MEM - Eagle) with 2 mM L-glutamine and Earle’s BSS adjusted to 
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contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium 
pyruvate, 90 %; fetal bovine serum, 10 %.  Cells were subsequently incubated at 37°C in an 
atmosphere composed of 95 % air and 5 % CO2 for 2 days.  
After 2 days, the culture medium was removed from the cells and discarded.  The cells 
were rinsed with 1 ml 0.25 % (w/v) Trypsin- 0.53 mM EDTA to remove all traces of serum that 
contained trypsin inhibitor.  The trypsin-EDTA solution was then removed.  1 ml of trypsin-
EDTA was subsequently added to the flask to detach the cells.  Cells were observed under a 
microscope until cell layer was dispersed (5-10 min).  9 ml of fresh growth culture medium 
(MEM) was immediately added to the flask to stop the trypsin reaction.  Cells were resuspended 
by gently pipetting.  A sample of the cells was removed to determine the cell density.  Once the 
density of the culture was known, cells were diluted and seeded at 105 cell/35mm glass bottom 
culture dish.  2 ml was added to each dish.  Cells in 35 mm dishes were placed in the incubator at 
37°C. 
Addition of LLOC484/D69C 6xHis-A488 to Vero Cells 
The following day, the cells were ready to be labeled with LLO-A488.  To prepare the 
cultures for fluorescence imaging, the cells were washed with 3x1 ml of cold PBS.  LLOC484/D69C 
6xHis-A488 was then diluted to a final volume of 1 ml in cold PBS and added to the Vero cells 
at concentrations of 1 nM, 2 nM, and 4 nM for each culture.  One 35 mm dish of Vero cells had 
only PBS added to serve as a negative control.  Each dish was incubated on ice for 5 min in the 
dark.  Unbound toxin was removed by washing with 3x1 ml of cold PBS.  500 μl of Para-
formaldehyde 4 % was added to each dish to fix the cells.  Cells were washed again with 3x1 ml 
cold PBS.  This protocol was followed with 2 additional dishes in which 2 nM of LLOD69C -
B r u g g e m a n  | 17 
 
A488 was added to the cells, the only difference being that the cells were also incubated at 37°C 
for 1 min and 5 min after the unbound toxin was removed.  
Images Acquired  
After the toxin had been applied to the Vero cells, cells were viewed using a Zeiss 
Observer D1 microscope under 100x objective.  Fluorescence and phase contrast images were 
acquired using MetaMorph computer software.  The average fluorescence intensity of the cells 
were calculated for each concentration of protein. 
C ­ Results and Discussion 
C.1 ­­ Site Directed Mutagenesis 
The QuikChange site directed mutagenesis kit (Stratagene) is a reliable and simple way 
to generate point mutations in plasmids.  The QuikChange protocol uses mutagenic primers, 
which overlap onto complementary DNA strands within a plasmid after denaturation.  The aim is 
to target a specific amino acid within the primer sequence to be mutated (Figure 3).  After 
attachment of the primers, PfuUltra DNA polymerase replicates the plasmid via PCR (Fig. 2).  
Over several cycles an abundance of mutated DNA that is not methylated is synthesized by 
PfuUltra.  The parental DNA, which had been methylated by the XL1-Blue E. coli, was 
successfully digested using DpnI, which left only the unmethylated DNA synthesized during 
PCR.  
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Figure 2.  QuikChange Site Directed Mutagenesis 
Protocol  
The OD260 and OD280 of the plasmids which were purified from the XL1-Blue cells were 
determined to be pure however lower than the desired concentration for sequencing of 50 ng/μl 
(Table 5).  The valine 274 to cysteine mutation was unsuccessful and no clones were obtained 
after transformation.  The protocol was continued with only the other three successful mutations.  
The concentrations of the purified clones which were submitted to sequencing are shown in 
Table 5. In spite of the low concentration of plasmid, all ratios were roughly 1.8 and the Plant 
Microbe Genomics Facility at Ohio State sequenced the plasmid successfully. 
Purified Clones  Concentration  OD260/OD280
LLOC484A‐6xHis ‐ #2  18 ng/μl  1.9 
LLOC484A‐6xHis ‐ #4  16.5 ng/μl  1.9 
LLOC484A/A27C‐6xHis  ‐ #3  21 ng/μl  1.83 
LLOC484A/A27C‐6xHis  ‐ #5  23.5 ng/μl  1.88 
LLOC484A/D69C‐6xHis  ‐ #1  80 ng/μl  1.85 
LLOC484A/D69C‐6xHis  ‐ #2  23.5 ng/μl  1.68 
LLOC484A/T275C‐6xHis  ‐ #3  58.5 ng/μl  1.77 
Table 5. List of purified plasmid DNA mutants that were used for further 
analysis along with their concentration and purity at the time of sequencing 
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The results from DNA sequencing revealed successful point mutations for all plasmids 
which were submitted to the Plant Microbe Genomics Facility for sequencing.  The cysteine-free 
mutant contained a point mutation of a Cys-to-Ala at the 484th amino acid, as desired. The other 
mutants, which were further constructions of the Cysfree toxin, revealed their desired point 
mutations.  Due to the success of the mutations of the genes encoding for LLO, we continued to 
the next stage of the experiment with confidence that the desired recombinant proteins could be 
purified. 
C.2 ­­ Protein Purification 
 The protocol required that the plasmids with mutated genes encoding for LLO be 
transformed into BL21 (DE3) E. coli. This strain of E.coli exhibits a high level of protein 
synthesis and permitted a high level of expression of LLO after induction with IPTG.  Figure 3 
shows the high level of LLO expression that resulted from induction with IPTG.  The induction 
of LLO in BL21 (DE3) E. coli was successful in all instances.  
 
kDa kDa 
 Figure 3. BL21(DE3) lysates before (A) and after (B) induction of LLOA27C . 
Arrows show LLOA27C (C) and LLOA27C–A488 (D).  Arrows show the 
LLOA27C toxin.  
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After induction of LLO, lysis of E. coli cells became a problem in the purification 
protocol.  Initially, the cells were sonicated on ice.  This protocol proved to be inefficient due to 
two problems.  The sonicator was not capable of efficiently lysing the cells for lower outputs.  
When the output was increased, the cells began to overheat and the LLO toxins denatured.  
Correcting these two problems was impossible, so a new strategy was developed.  The new 
strategy involved lysing cells in an MM200 (Retsch).  This strategy was effective.  The cells did 
not overheat using this method and were well lysed.   
Purification of the protein via affinity chromatography was successful.  This protocol 
involved binding of the Ni-NTA matrix to the 6xHis tag at the C-terminus of the recombinant 
toxins.  This is the result of interactions of the Ni2+ ions with the 6xHis tag.  The 6xHis tag and 
the Ni-NTA matrix were successfully bound by incubation and rotation.  The high yield of 
protein after elution and analysis on an SDS-PAGE gel indicated that the protein and matrix 
were successfully bound (Figure 3). 
After the wash steps, the proteins were successfully eluted.  The protein was present at a 
high concentration in elution fraction #2 based on results of the DC protein assay.  SDS-PAGE 
gel and Western Blot results revealed that the LLO toxin with a 6xHis tag was successfully 
purified.  The concentrations based upon the OD280 readings for each recombinant toxin were 8.5 
mg/ml for LLOA27C, 3.46 mg/ml for LLOD69C, and 9.88 mg/ml for LLOT275C (Table 6).  
Recombinant Toxins Concentration 
LLOA27C 8.5 mg/ml 
LLOD69C 3.46 mg/ml 
LLOT275C 9.88 mg/ml 
Table 6. Concentration of each recombinant 
toxin after purification via affinity 
chromatography. 
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C.3 ­­ Fluorescent Labeling 
The successfully purified LLO toxins were then covalently conjugated to the Molecular 
Probe Alexa-Fluor 488 C5 Maleimide (Invitrogen).  Alexa Fluor 488 is known to be the best 
green-fluorescent reactive dye available and it has a high level of photostability.  Alexa Fluor 
488 has an excitation/emission maxima of 495/519 nm.  The maleimide binds to the unique 
cysteine residue in the LLO toxin.  The cysteine residue originally located in domain 4 (Cys 484) 
was removed from the undecapeptide sequence in domain 4 of the protein, because oxidation of 
this cysteine inhibits the pore forming ability of the toxin (3). 
The elution profiles of the fractions from Sephadex gel filtration chromatography show 
that the fluorescent labeling was effective (Figure 4).  The protocol revealed a successfully 
labeled protein that was eluted in the 5th fraction sample. The elution also clearly showed that the 
unbound dye was eluted after the labeled protein.  The toxin in this fraction had a dye/ protein 
ratio of 0.88 (Figure 5).  The negative control, LLOC484A, revealed that there was unbound dye in 
elution 5.  LLOC484A had a dye/ protein ratio of 0.3, which was likely a result of electrostatic 
reactions between the negatively charged Alexa Fluor 488 dye and the positively charged amino 
acids within the protein sequence.  Because of these results, it was clear that the protein was 
labeled; however, perhaps to a lesser degree than what was being calculated.  The results of 
fluorescent coupling were dye/ protein ratios of 0.92 for LLOA27C, 0.85 for LLOD69C, and 0.97 
for LLOT275C.  The concentration of protein and dye in the other elution fractions of gel filtration 
were not determined, because the protein had very clearly eluted into the 5th fraction. 
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Figure 4. Elution profiles of LLOWT-A488 and free dye. 
Fraction 5 is collected. 
C.4 ­­ Hemolytic Assay 
A hemolytic assay was performed as an indicator of the pore-forming ability of the toxins 
by measuring the lysis of sheep red blood cells (SRBCs).  LLO binds to red blood cells and lyses 
them by oligomerizing and forming pores.  The results of the hemolytic assay demonstrated that 
the recombinant, labeled toxins maintained hemolytic ability.  The LLOA27C maintained complete 
hemolytic ability and exhibited 50 % hemolysis at a concentration of 0.7 nM, which actually 
proved better than the LLOWT, which had 50 % hemolysis at 1 nM.  The other two recombinant 
toxins, LLOD69C, and LLOT275C maintained approximately 50 % hemolysis when compared to the 
LLOWT.  Their concentrations at 50 % lysis were 1.8 nM (Figure 5).  Because of these results, all 
3 fluorescently labeled recombinant toxins were determined to be capable of forming pores. 
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Figure  5. The hemolytic curves were determined by the level of hemoglobin 
released from a 0.2 % suspension of SRBCs measured at 450 nm.  
C.5 ­­ Fluorescence Imaging 
Toxins were added to the cell at 4°C, a temperature that impedes all internalization of the 
membrane, therefore if the toxin interacts with the cell, they do so by association with the plasma 
membrane.  LLOD69C-A488 proved effective at interacting with Vero cells.  The toxin was 
clearly visible during acquisition of the cell images.  The cells that were incubated on ice for 5 
min with the toxin demonstrated increased levels of fluorescence intensity when the 
concentration of protein added was increased (Figure 7). The cell cultures that contained 2 nM of 
toxin and were incubated at 37°C so that the toxin had the opportunity to perforate the cells 
showed that LLO was perforating the membrane and invading the cells. The cells incubated for 1 
minute did not display internalization, however, the cells that were incubated for 5 minutes were.  
This revealed that the cell was being lysed at a point between 1 min and 5 min at a concentration 
of 2 nM of toxin.  Images that demonstrate this have been provided (Figure 6).  6 images were 
acquired under phase contrast and with a GFP filter so that the average fluorescence intensity of 
the cells at each concentration of toxin could be determined.  The cells that contained 0 nM, 1 
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nM, 2 nM, and 4 nM of toxin displayed an average fluorescence intensity of 26.8/pixel, 
72.9/pixel, 89.6/pixel, and 172.3/pixel, respectively (Figure 7).  These results demonstrated that 
the fluorescent recombinant toxins bind to mammalian membranes and form pores in the host 
membrane. Therefore, the goal of this project was acheived.  Three fluorescent recombinant LLO 
toxins were obtained that could bind to host cell membranes, form pores, and be efficiently 
visualized by fluorescence microscopy. 
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Figure 7.  Graphic display of the average fluorescence intensity associated to the Vero 
cells 
 
D ­ Future Research 
A fluorescent LLO which maintains pore-forming capability has been obtained for the 
first time.  These fluorescently labeled LLO toxins can be used to study the interactions of LLO 
with host cells in order to determine the dynamics of toxin clustering and interaction with 
membrane lipid rafts.  Also fluorescent toxin will provide a powerful tool to determine the 
internalization pathway and intracellular trafficking of the toxin.  Through the knowledge gained 
from better understanding the interactions of CDCs such as LLO with host cells we can begin to 
refine the design of antitoxins to fight infectious diseases. 
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